Related Experiment Video
Updated: Jun 10, 2026
08:17
Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
Published on: August 25, 2017
New therapies for chronic obstructive pulmonary disease
1National Heart and Lung Institute, Imperial College London, Dovehouse Street, London SW3 6LY, UK. p.j.barnes@imperial.ac.uk
Summary
Chronic obstructive pulmonary disease (COPD) treatments are limited. New therapies targeting inflammation, such as CXCR2 antagonists and histone deacetylase-2 activators, show promise for improving COPD outcomes.
Area of Science:
- Pulmonary Medicine
- Pharmacology
- Inflammation Research
Background:
- Chronic obstructive pulmonary disease (COPD) is a progressive global health issue with high mortality.
- Current treatments, primarily long-acting bronchodilators, do not halt disease progression or reduce mortality.
- COPD pathophysiology involves chronic inflammation, a key area for therapeutic intervention.
Purpose of the Study:
- To review current and emerging therapeutic targets for COPD.
- To evaluate novel anti-inflammatory strategies beyond standard bronchodilators.
- To explore approaches for overcoming corticosteroid resistance in COPD.
Main Methods:
- Review of existing literature on COPD pathophysiology and treatment.
- Analysis of novel drug targets, including mediator antagonists and broad-spectrum anti-inflammatory agents.
- Discussion of strategies to enhance the efficacy of anti-inflammatory therapies.
Main Results:
- Long-acting bronchodilators are the current standard but do not prevent progression.
- CXCR2 antagonists show potential for reducing neutrophil and monocyte recruitment.
- Broad-spectrum anti-inflammatory drugs (e.g., PDE4, p38 MAPK, NF-kappaB, PI3K inhibitors) are being investigated, with inhaled delivery potentially mitigating side effects.
- Reversing corticosteroid resistance by increasing histone deacetylase-2 activity is a promising strategy.
Conclusions:
- Novel therapeutic strategies are needed to address the limitations of current COPD treatments.
- Targeting inflammatory pathways, such as neutrophil recruitment via CXCR2 antagonism, offers new possibilities.
- Enhancing histone deacetylase-2 activity presents a promising approach to overcome corticosteroid resistance and manage COPD inflammation.
Related Concept Videos
01:29Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:24Chronic Obstructive Pulmonary Disease
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:30Chronic Obstructive Pulmonary Disease-V: Nursing Management
Nursing management of Chronic Obstructive Pulmonary Disease (COPD) is crucial for providing thorough care and support to patients. Nurses play an integral role in this process through detailed assessment, careful planning, targeted interventions, and ongoing evaluation. Here's an overview of the critical steps in nursing management for COPD.
Assessment
Assessment